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Abstract: Proton beam therapy (PBT) offers significant benefit over conventional (photon) radiotherapy
for the treatment of a number of different human cancers, largely due to the physical characteristics.
In particular, the low entrance dose and maximum energy deposition in depth at a well-defined region,
the Bragg peak, can spare irradiation of proximal healthy tissues and organs at risk when compared to
conventional radiotherapy using high-energy photons. However, there are still biological uncertainties
reflected in the relative biological effectiveness that varies along the track of the proton beam as a
consequence of the increases in linear energy transfer (LET). Furthermore, the spectrum of DNA
damage induced by protons, particularly the generation of complex DNA damage (CDD) at high-LET
regions of the distal edge of the Bragg peak, and the specific DNA repair pathways dependent on
their repair are not entirely understood. This knowledge is essential in understanding the biological
impact of protons on tumor cells, and ultimately in devising optimal therapeutic strategies employing
PBT for greater clinical impact and patient benefit. Here, we provide an up-to-date review on the
radiobiological effects of PBT versus photon radiotherapy in cells, particularly in the context of DNA
damage. We also review the DNA repair pathways that are essential in the cellular response to PBT,
with a specific focus on the signaling and processing of CDD induced by high-LET protons.
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1. Introduction
Since its first application in the 1950s, proton beam therapy (PBT) is gaining ground in radiation
oncology thanks to its radiobiological and physical advantages over photon radiotherapy [1]. Proton
beams are characterized by a low entrance dose, whereby the protons lose energy along the track and
just before they stop, the dose peaks in depth at a narrow and well-defined range called the Bragg
peak (Figure 1A). The energy deposition drops rapidly shortly after the peak at the distal fall-off.
This spares the surrounding tissue and organs at risk (OARs) in close proximity to the tumor being
treated. A combination of beams with different initial energies can produce a wider peak, the so-called
spread-out Bragg peak (SOBP), allowing the irradiation of larger target tumor volumes [2] (Figure 1B).
However, as the protons slow down and lose energy further, their linear energy transfer (LET) increases
and becomes maximal in the distal fall-off of the Bragg peak.
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Figure 1. Depth–dose distribution of protons and relationship to energy and linear energy transfer 
(LET). (A) An unmodulated (pristine) Bragg peak produced by a proton beam. (B) Spread‐out Bragg 
peak (SOBP) from several modulated proton beams. 
As  of  now,  there  are  70  operative  facilities worldwide  for  PBT  and  42  under  construction 
according to the Particle Therapy Co‐Operative Group (https://www.ptcog.ch), with 150,000 patients 
receiving  PBT  treatment. Despite  over  60  years  of  therapeutic  use  of  protons,  there  are  several 
uncertainties regarding the relative biological effectiveness (RBE) of the proton beam along the track, 
particularly throughout the SOBP where there are differences in proton energy and, therefore, LET. 
There  is  also  a  lack  of  understanding  of  the  DNA  damage  induced  by  PBT,  particularly  the 
complexity and relative levels of clustered/complex DNA damage (CDD) induced by protons at the 
distal edge of the Bragg peak. Consequently, the cellular DNA damage response (DDR) and repair 
pathways that are required for resolving CDD generated by PBT are not fully understood. Related to 
this, individual human cancers will furthermore display inherent differences in radiosensitivity to 
PBT, of which proteins involved in the DDR play such an important role. These uncertainties limit 
our ability to use PBT to its full advantage, by exploiting tumor killing while reducing the exposure 
of healthy tissue [3]. 
In this review, we provide the latest knowledge of the radiobiology of PBT, particularly in the 
context of DNA damage and the repair pathways that are important for the cellular DDR, and discuss 
the areas where ongoing research is necessary, which will have a major impact on the effective clinical 
use of PBT for cancer treatment. 
2. Relative Biological Effectiveness (RBE) and Linear Energy Transfer (LET) 
RBE is used to correlate PBT to photon radiotherapy, as is it the ratio of the reference radiation 
(photon) dose to the dose of protons required to cause the same biological effect. In clinical practice, 
a constant RBE value of 1.1 is utilized throughout the Bragg curve, despite the ongoing debate about 
whether this is the optimal solution or not [3–5]. RBE depends on both physical factors such as the 
proton beam energy, the dose fractionation and dose rate, and biological factors including the type 
of the tissue, cell‐cycle stage, the oxygenation level, and the position of irradiation along the SOBP 
[5–7]. Experimental  evidence  largely derived  from  in  vitro  clonogenic  survival  assays using PBT 
facilities ranging from 65–250 MeV have demonstrated that the RBE value is variable and increases 
with decreasing dose  [3,5,8,9].  In spite of  the  large  fluctuation derived  from  in vitro data and  the 
biological uncertainty, a constant RBE of 1.1  is used clinically  to minimize  the potential  for  risks 
[3,7,10,11]. One of the parameters mainly determining RBE values is the LET, which is the energy loss 
and deposition  along  the  path  of  the proton  beam  and  is  a measure  of  ionization density  [3,5]. 
Therefore,  the higher  the LET  is,  the denser  the  ionization events are, resulting  in more extensive 
damage induction. High‐energy PBT is considered low‐LET irradiation; however, as the proton beam 
energy  decreases  throughout  the  SOBP,  the  LET  increases  particularly  at  the  distal  edge. 
Consequently, RBE values have been reported to rise from ~1.1 in the entrance, to ~1.2 in the center, 
~1.4 at the distal edge, and ~1.7 in the distal fall‐off the SOBP [11,12]. However, RBE values at the 
Figure 1. Depth–dose distribution of protons and relationship to energy and linear energy transfer
(LET). (A) An unmodulated (pristine) Bragg peak produced by a proton beam. (B) Spread-out Bragg
peak (SOBP) from several modulated proton beams.
As of now, there are 70 operative facilities worldwide for PBT and 42 under construction according
to the Particle Therapy Co-Operative Group (https://www.ptcog.ch), with 150,000 patients receiving
PBT treatment. Despite over 60 years of therapeutic use of protons, there are several uncertainties
regarding the relative biological effectiveness (RBE) of the proton beam along the track, particularly
throughout the SOBP where there are differences in proton energy and, therefore, LET. There is also a
lack of understanding of the DNA damage induced by PBT, particularly the complexity and relative
levels of clustered/complex DNA damage (CDD) induced by protons at the distal edge of the Bragg
peak. Consequently, the cellular DNA damage response (DDR) and repair pathways that are required
for resolving CDD generated by PBT are not fully understood. Related to this, individual human
cancers will furthermore display inherent differences in radiosensitivity to PBT, of which proteins
involved in the DDR play such an important role. These uncertainties limit our ability to use PBT to its
full advantage, by exploiting tumor killing while reducing the exposure of healthy tissue [3].
In this review, we provide the latest knowledge of the radiobiology of PBT, particularly in the
context of DNA damage and the repair pathways that are important for the cellular DDR, and discuss
the areas where ongoing research is necessary, which will have a major impact on the effective clinical
use of PBT for cancer treatment.
2. Relative Biological Effectiveness (RBE) and Linear Energy Transfer (LET)
RBE is used to correlate PBT to photon radiotherapy, as is it the ratio of the reference radiation
(photon) dose to the dose of protons required to cause the same biological effect. In clinical practice, a
constant RBE value of 1.1 is utilized throughout the Bragg curve, despite the ongoing debate about
whether this is the optimal solution or not [3–5]. RBE depends on both physical factors such as the
proton beam energy, the dose fractionation and dose rate, and biological factors including the type of
the tissue, cell-cycle stage, the oxygenation level, and the position of irradiation along the SOBP [5–7].
Experimental evidence largely derived from in vitro clonogenic survival assays using PBT facilities
ranging from 65–250 MeV have demonstrated that the RBE value is variable and increases with
decreasing dose [3,5,8,9]. In spite of the large fluctuation derived from in vitro data and the biological
uncertainty, a constant RBE of 1.1 is used clinically to minimize the potential for risks [3,7,10,11]. One
of the parameters mainly determining RBE values is the LET, which is the energy loss and deposition
along the path of the proton beam and is a measure of ionization density [3,5]. Therefore, the higher the
LET is, the denser the ionization events are, resulting in more extensive damage induction. High-energy
PBT is considered low-LET irradiation; however, as the proton beam energy decreases throughout the
SOBP, the LET increases particularly at the distal edge. Consequently, RBE values have been reported
to rise from ~1.1 in the entrance, to ~1.2 in the center, ~1.4 at the distal edge, and ~1.7 in the distal
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fall-off the SOBP [11,12]. However, RBE values at the distal fall-off were shown to rise to over 3, which
is supported by two other studies using clonogenic survival assays indicating RBE values of up to
2.3 [13] and 3.5 [14]. Furthermore, a dose shift around the distal edge where the biological dose extends
beyond the range of the SOBP can threaten proximal healthy tissue, potentially causing unexpected
side effects [15]. Interestingly a recent in vivo study using rat cervical spinal cords irradiated at four
different positions of an SOBP demonstrated that RBE values varied from 1.1 to 1.3, dependent on
LET [16]. The uncertainties and challenges with RBE are not covered at length here, and we refer the
reader to the literature cited above and more recent reviews [17,18].
3. Radiobiological Effects of Protons
3.1. DNA Damage and Repair
The therapeutic effect of PBT, similar to conventional radiotherapy techniques, relies on significant
DNA damage within tumorous cells leading to cell death. A variety of DNA lesions are induced along
the radiation track (Figure 2), which include DNA base damage, sites of base loss (abasic sites), and
DNA single-strand breaks (SSBs) that are most abundantly generated. On the other hand, the formation
of DNA double-strand breaks (DSBs) and complex DNA damage (CDD) containing two or more DNA
lesions in close proximity (within 1–2 helical turns of the DNA [19]) are less frequent, although these
are considered the most lethal [20–22]. However, human cells have developed a sophisticated signaling
network, the cellular DDR, which detects and repairs these DNA lesions [23]. DSBs are mainly resolved
via two repair pathways, non-homologous end-joining (NHEJ) and homologous recombination (HR)
(reviewed in [24,25]). Pathway choice is partly dependent on cell-cycle stage, with NHEJ mostly active in
G0/G1, whereas HR is active in S/G2 phases [26]. NHEJ can be further divided into classical NHEJ, which
involves the Ku70/80 heterodimer that binds to the DSB ends and recruits the DNA-dependent protein
kinase catalytic subunit (DNA-Pkcs), and X-ray repair cross-complementing protein 4 (XRCC4)–DNA
ligase IV that promotes the end-joining reaction (Figure 2B). Whereas alternative NHEJ involves
DNA end resection by the MRE11–RAD50–NBS1 (MRN) complex, poly(ADP-ribose) polymerase-1
(PARP-1) that binds to the DNA ends, and X-ray repair cross-complementing protein 1-DNA ligase
IIIα (XRCC1-Lig IIIα) or DNA ligase I (Lig I) that seals the DSB (Figure 2C). During HR, the DNA
undergoes end resection by the MRN complex and the 3′-single stranded DNA is coated by replication
protein A (RPA) and RAD51 that promotes invasion into the sister chromatid. DNA synthesis is
followed by resolution of Holliday junctions before completing repair (Figure 2D). CDD, given that this
contains localized damage over short distances within the DNA, can include a mixture of DNA base
damage, abasic sites, SSBs, and DSBs [27]. This, therefore, represents a major barrier to the cellular
DDR for efficient repair; however, considering the nature of the damage, it is assumed that these CDD
sites will require the relevant proteins involved in base excision repair (BER), as well as DSB repair.
BER is generally coordinated through the action of damage-specific DNA glycosylases that excise the
damaged DNA bases, AP-endonuclease 1 (APE1) that incises the resulting abasic sites and generates
an SSB for PARP-1 binding, DNA polymerase β (Pol β) that removes the 5′-deoxyribosephosphate
moiety and inserts the correct undamaged nucleotide, and a complex of XRCC1–Lig IIIα that seals the
SSB [28,29] (Figure 2A).
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Figure 2. The response to ionising radiation (IR)‐induced DNA damage. Proton beam therapy (PBT), 
similar  to  other  radiotherapy  techniques,  targets DNA  and  can  generate  an  abundance  of DNA 
lesions,  where  oxidative  DNA  base  damage,  abasic  sites,  and  single‐strand  breaks  (SSBs) 
predominate, and which are repaired via (A) the base excision repair (BER) pathway. This involves 
recognition of the damaged base by a damage specific DNA glycosylase, incision of the abasic site by 
AP‐endonuclease  1  (APE1)  and  SSB  binding  by  poly(ADP‐ribose)  polymerase‐1  (PARP‐1),  5’‐
deoxyribosephosphate  (dRP)  removal  and  gap  filling  by DNA polymerase  β  (Pol  β),  and  finally 
ligation by X‐ray repair cross‐complementing protein 1‐DNA ligase III (XRCC1–Lig III) complex. 
Double‐strand breaks (DSBs) are repaired by different pathways dependent on cell‐cycle phase. In 
the G0/G1  phases, DSBs  are  repaired  by  either  (B)  classical  non‐homologous  end‐joining  (NHEJ) 
involving Ku70/80 that binds to the DNA ends, followed by DNA‐dependent protein kinase catalytic 
subunit  (DNA‐Pkcs) and XRCC4–Lig  IV  that promote DNA  ligation, or via  (C) alternative NHEJ 
which involves DSB end resection by the MRE11–RAD50–NBS1 (MRN) complex, PARP‐1 binding to 
the DSB ends, and subsequent repair by Lig I or XRCC1–Lig III. In the S/G2 phases of the cell cycle, 
DSB repair  is achieved by  (D) homologous recombination  (HR) which uses a sister chromatid  for 
repair. Therefore, following DNA end resection by the MRN complex, replication protein A (RPA) 
and RAD51 bind to the single‐stranded DNA overhangs that promote strand invasion and subsequent 
DNA synthesis  in  the presence of RAD52/RAD54, as well as  formation and  resolving of Holliday 
junctions. The induction of complex DNA damage (CDD), consisting of several DNA lesions in close 
proximity, particularly by high‐LET protons at the distal edge of the SOBP, likely require multiple 
pathways for repair. 
3.2. DNA Damage Induction and Repair Following PBT 
Protons, as particles with mass and positive charge, interact with tissue completely differently 
from photons which have neither mass nor charge, although the specific physical aspects (e.g., beam 
intensity, LET,  and  secondary particle  spectra) depend  very much  on  the proton  beam delivery 
system [30]. Consequently, DNA damage induction and the mechanisms of DNA repair employed 
are reportedly different between PBT and conventional radiotherapy [31]. Most of the focus of current 
Figure 2. The response to ionising radiation (IR)-induced da age. Proton bea therapy (PBT),
si ilar to other radiotherapy techniques, targets DNA and can generate an abundance of DNA lesions,
where oxidative DNA base damage, abasic sites, and single-strand breaks (SSBs) predominate, and
which are repaired via (A) the base excision repair (BER) pathway. This involves recognitio of the
damaged base by a damage specific DNA glycosylase, incision of the basic site by AP-endonuclease
1 (APE1) and SSB binding by poly(ADP-ribose) polymerase-1 (PARP-1), 5’-d oxyribosephosphate
( RP) emoval and gap filling by DNA polymerase β (Pol β), and finally ligation by X-ray repair
cross-complementing protein 1-DNA ligase IIIα (XRCC1–Lig IIIα) complex. Double-strand breaks
( SBs) are repaired by different pathways depen ent o cell-cycle phase. I the G0/G1 phases, DSBs are
repaired by either (B) cla sical non-homologous nd-joining (NHEJ) involving K 70/80 that binds to the
DNA ends, followed by DNA-dependent protein kinase catalytic subunit (DNA-Pkcs) and XRCC4–Lig
IV that promote DNA ligation, or via (C) alternative NHEJ which involves DSB end resection by the
MRE11–RAD50–NBS1 (MRN) omplex, PARP-1 binding to the DSB ends, and subsequent repair by Lig
I or XRCC1–Lig IIIα. In the S/G2 hases of the cell cycle, DSB repair is achieved by (D) homologous
recombin tion (HR) which uses a sister chr matid for rep ir. Therefore, following DNA end esection by
the MRN complex, replication protein A (RPA) and RAD51 bind to the singl -stranded DNA overhangs
that promote strand invasion and subsequent DNA synthesis in th p esence of RAD52/RAD54, as
well as formation and resolvi g of Holliday junctions. The induction of complex DNA damage (CDD),
co sisti g of several DNA lesions in close proximity, parti ularly by high-LET protons at the distal
edge of the SOBP, likel require multi le pathways for repair.
3.2. DNA Damage Induction and Repair Following PBT
Protons, as particles with mass and positive charge, interact with tissue completely differently from
photons which have neither mass nor charge, although the specific physical aspects (e.g., beam intensity,
LET, and secondary particle spectra) depend very much on the proton beam delivery system [30].
Consequently, DNA damage induction and the mechanisms of DNA repair employed are reportedly
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different between PBT and conventional radiotherapy [31]. Most of the focus of current studies is on
examining the induction of DSBs, given that they are one of the major contributors, along with CDD,
to cell lethality post-irradiation (Table 1). Firstly, a significantly higher level (~1.2–1.6-fold) of DSBs,
particularly at 30 min post-irradiation, via analysis of phosphorylated histone variant H2AX (γH2AX)
foci, was shown for a 200 MeV PBT source compared to 10 MV photons in two human tumor cell
lines, ONS76 medulloblastoma cells and MOLT4 leukemia cells [32]. The disparities in foci number
diminished after 6 h post-irradiation, although it was reported that the PBT-induced γH2AX foci in the
ONS76 cells appeared to be ~1.2–1.5-fold larger in size, indicating a possible CDD phenotype. The fact
that these foci were resolved with similar kinetics would, however, argue that these DSBs are possibly
not complex in nature, given that CDD sites usually take a longer time to resolve. Similarly, the number
of DSBs in SQ23B head and neck squamous cell carcinoma (HNSCC) cells measured by pulse-field gel
electrophoresis was found to be ~1.2-fold higher for both 76 MeV and 201 MeV PBT sources than with
photons induced by γ-irradiation [9]. Yet interestingly, DSB numbers were not significantly different
between the two PBT energies or at different positions (entrance, mid, and distal) relative to the SOBP,
and any potential differences in kinetics of DSB repair were not reported. Numbers of both DSBs and
SSBs were also shown to be significantly higher (~1.2–1.6-fold increases in comet percentage tail DNA)
in glioblastoma stem-like cells treated with protons in comparison to 320 kV X-rays, particularly at
20–48 h post-irradiation, which was associated with a higher level of apoptosis [33]. In contrast to
the above studies, the numbers of γH2AX and 53BP1 foci (as DSB markers) induced in TrC1 prostate
cancer cells and murine embryonic fibroblasts irradiated at the entrance dose of a 187 MeV PBT beam
compared to 320 kV photons were observed to be the same 30 min post-irradiation [34]. The kinetics
of DSB repair, specifically the resolving of γH2AX and 53BP1 foci, were also shown to be similar
in response to the two irradiation conditions. This is supported by equal numbers of 53BP1 foci
induced in AG01522 skin fibroblasts 30 min post-irradiation at the entrance dose, and their repair up
to 24 h post-irradiation, of a 60 MeV proton beam compared to 225 kV X-rays [35]. Additionally, it
was demonstrated that the initial level of induction of DSBs (γH2AX foci) was the same in wild-type,
HR-deficient, and NHEJ-deficient Chinese hamster ovary cell lines following 1 Gy irradiation with
low-LET 138 MeV PBT and 200 kV X-rays [36]. However PBT resulted in further reduced clonogenic
survival in wild-type cell lines versus X-ray irradiation, suggesting that the quality of DNA damage
(e.g., formation of CDD) is what differs between PBT and X-rays and their effectiveness in cell killing,
although differences in levels of CDD was not proven directly.
Our recent study, using the neutral comet assay, demonstrated that the kinetics of repair of DSBs
induced by the entrance dose of a proton beam (58 MeV) versus 100 kV X-rays in HeLa and HNSCC
cells are not significantly different [37]. This would indicate that the nature and complexity of the
DSBs following the two irradiation conditions are similar. Likewise, the kinetics of SSB/abasic site
repair using the alkaline comet assay were comparatively the same. Furthermore, we observed that
low-energy protons generated at the distal edge of a SOBP (11 MeV mean energy incident on the cells)
had no impact on the repair of DSBs in both HeLa and HNSCC cells in comparison to 58 MeV protons
and 100 kV X-rays, even though there was a significant difference in clonogenic survival between the
proton irradiation conditions. However, we observed a significant delay in the repair of SSB/abasic
sites only following low-energy proton irradiation. In fact, levels of SSBs were ~4–7-fold higher 2 h
post-irradiation under these conditions, in comparison to cells irradiated with 58 MeV protons. This
suggested that low-energy protons can generate CDD that is largely SSB-associated, which persists
for several hours (>2 h) post-irradiation and contributes to decreased cell survival, although the
specific nature and composition of the CDD under these conditions requires further research (see also
Section 3.5).
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Table 1. Comparisons of double-strand breaks (DSBs) induced by proton beam therapy (PBT) versus
photon irradiation.
Cell Line Method(s) Proton Energy Photon Energy Observation (Proton vs.Photon) Ref
ONS76 medulloblastoma;
MOLT4 leukemia cells
γH2AX foci by
immunofluorescence 200 MeV
10 MV
X-rays
~1.2–1.6-fold increase in
DSB foci and ~1.2–1.5-fold
larger in size 30–180 min
post-irradiation
[32]
HeLa; SQ20B HNSCC cells Pulse-field gelelectrophoresis
76 MeV,
201 MeV
622 keV 137Cs
γ-rays
~1.2-fold increase in DSBs.
No differences between PBT
energies, nor along the SOBP
[9]
IN528 and T4213
glioblastoma stem-like cells
Alkaline and neutral
comet assay N.S.
320 kV
X-rays
~1.2–1.6-fold higher
numbers of DSBs at 20–48 h
post-irradiation
[33]
TrC1 prostate cancer cells;
murine embryonic
fibroblasts
Histone γH2AX and
53BP1 foci by
immunofluorescence
187 MeV
entrance dose
320 kV
X-rays
Similar numbers of DSBs at
0.5–24 h post-irradiation [34]
AG01522 skin fibroblasts 53BP1 foci byimmunofluorescence
60 MeV
entrance dose
225 kV
X-rays
Similar numbers of DSBs at
0.5–24 h post-irradiation [35]
Wild-type, HR-, and
NHEJ-deficient Chinese
hamster ovary cell lines
Histone γH2AX foci
by
immunofluorescence
138 MeV 200 kVX-rays
Similar initial induction of
DSBs [36]
HeLa; UMSCC74A and
UMSCC6 HNSCC cells Neutral comet assay
58 MeV
entrance dose;
11 MeV distal
edge
100 kV
X-rays
No difference in DSB repair
kinetics [37]
N.S. refers to not specified. HR—homologous recombination; NHEJ—non-homologous end-joining; SOBP—spread-out
Bragg peak.
3.3. Generation of Reactive Oxygen Species and Cell-Cycle Progression Following PBT
Related to DNA damage induction is the generation of reactive oxygen species (ROS). Interestingly,
a more rapid and prominent increase in ROS following PBT was reported in neural precursor cells from
rat hippocampus exposed to either 250 MeV protons near the Bragg peak, versus 250 kV X-rays [38].
Proton-induced ROS peaked 6 h post-irradiation and was ~1.5-fold above the control levels, while
photon-induced ROS peaked 12 h post-irradiation and was ~1.3-fold above the control levels at a 5 Gy
dose equivalent. However, less prominent increases and time-dependent differences in ROS levels
were observed at a 1 Gy dose. Furthermore, it was shown that protons were more effective in killing
cancer stem-like cells derived from non-small-cell lung cancer cell lines, and that compared to photons,
protons induced higher levels (~1.1–1.7-fold) of ROS after treating these cells with equivalent doses
of radiation [39]. ROS were also demonstrated to play an important role in inducing cytotoxicity of
glioblastoma stem-like cells treated with protons, and ROS levels were ~1.8-fold higher following
protons versus 320 kV X-rays at 20 h post-irradiation, which led to increased cellular apoptosis [33].
Levels of ROS were continually and dramatically higher (~6–7-fold) three days following protons in
comparison to photons.
Cell-cycle progression is another important factor related to proton-induced DNA damage, as
DNA damage checkpoints will be activated to allow cells to undergo extensive DNA repair prior to
DNA synthesis or replication. This is also important for understanding the repair pathway choice (see
Section 3.4), given that DSBs can be repaired by either NHEJ or HR in different cell-cycle phases. One
study conducted using human lung cancer cells suggested that, following 62 MeV protons, CRL5876
cells appeared to accumulate (~2-fold increase) in the G1 phase at 24 h post-irradiation, but that both
CRL5876 and HTB177 cells accumulate (~1.5–2-fold increase) in G2/M at 48 h post-irradiation, versus
unirradiated controls [40]. However, no comparisons against photon irradiation were performed. We
also recently noted an accumulation (~1.5-fold increase) of HeLa cells in G2/M, particularly at 8–24 h
post-irradiation with 58 MeV PBT, which was not LET-dependent as the same observation was seen
with cells irradiated with low-energy protons generated at the distal edge of a SOBP (11 MeV mean
energy incident on the cells) at higher LET [37,41]. This, however, suggests that CDD induced by
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high-LET protons, at least under the conditions analyzed, is not a major contributory factor to the
observed cell-cycle checkpoint activation. An early study observed G2 arrest of glioblastoma cells at
24–72 h post-irradiation following 5.7 MeV protons at relatively high-LET, which was more pronounced
(~1.5–2.5-fold) than irradiation of cells using 120 kV X-rays [42], suggesting potential proton-specific
effects. In contrast, there was no dramatic difference in cell-cycle distribution of Chinese hamster ovary
cells when comparing the response to low-LET 138 MeV PBT and 200 keV X-rays, where a degree of
G2/M accumulation (~1.2–2-fold increase) of cells irradiated at 5 Gy dose equivalent, particularly at
6–12 h following both irradiation types, was observed [36]. Furthermore, it was shown that proton
irradiation of glioblastoma stem-like cells actually led to a shortened G2/M arrest compared to 320 kV
X-ray irradiation, as demonstrated by a ~2-fold accumulation of cells in this cell-cycle phase at six days
post-irradiation following photon irradiation only [33]. However, the baseline levels of cells in G2/M in
this study were noticeably different (~10 and 20 %) in the experiments comparing proton and photon
irradiation. Given the variability in the observations, more studies to directly compare progression
of cells through the cell cycle in response to protons versus photons in specific cell models, and the
impact of LET need to be performed.
3.4. DSB Repair Pathway Choice Following PBT
NHEJ is considered the primary mechanism for DSB repair, particularly in response to photon
irradiation, but there are a few conflicting reports to date suggesting that the DNA repair pathway
choice specifically following PBT may in fact be different (Table 2). Firstly, by studying DNA repair
kinetics in wild-type, NHEJ-deficient (XRCC4 and DNA-Pkcs) and HR-deficient (XRCC2 and XRCC3)
Chinese hamster cell lines exposed to photon (γ-irradiation) versus low-LET 200 MeV protons, the
same biological effect was observed in each cell line comparing the two radiation types [43]. Therefore,
a delayed decrease in γH2AX foci at 3–12 h post-irradiation, as well as significantly reduced clonogenic
survival, was observed in DNA-Pkcs-deficient cells in comparison to wild-type cells. However,
HR-deficient cells also displayed increased sensitivity to protons and photons, and significantly higher
chromosomal aberrations (~2–4-fold increases) were found in both NHEJ- and HR-deficient cells
compared to the wild-type cells following both radiation types. From this study, it was suggested
that NHEJ is the major pathway, and DNA-Pkcs is the main protein involved in resolving DSBs
induced not only by photons but also by low-LET protons. This is supported by another study
demonstrating that there were no significant differences in γH2AX foci formation and their repair
in wild-type and DNA-Pkcs-deficient Chinese hamster ovary cell lines in response to γ-irradiation
versus low-LET protons [44]. Persistent γH2AX foci was observed in the DNA-Pkcs-deficient cells
6 h post-irradiation with higher doses (2-3 Gy) of photons or protons, correlating with increased
radiosensitivity versus wild type cells. In contrast using a similar experimental set-up of Chinese
hamster ovary cell lines deficient in HR (XRCC3) or treated with small interfering RNA (siRNA)
targeting RAD51 and comparing low-LET 138 MeV proton and 200 kV photons, it was suggested that
PBT induced more lethal chromosomal aberrations [36]. Moreover, this study reported that PBT was
more effective in killing HR-deficient cell lines than NHEJ-deficient cells and, therefore, there was an
enhanced dependence on HR for repair of proton-induced DSBs. The same conclusion was found
following an examination of low-LET PBT (138 MeV) versus 200 kV photon irradiation in human
tumor cells that were treated with siRNA or inhibitors targeting key proteins involved in HR and
NHEJ [45]. It was found that DNA-Pkcs inhibition significantly radiosensitized A549 lung cancer and
glioblastoma cells to photon-irradiated cells, but that this was to a lesser degree following low-LET PBT.
Photon-irradiated cells in the presence of the inhibitor also showed delayed resolving of γH2AX foci at
6–24 h post-irradiation which were ~1.5–3-fold higher than the corresponding cells following proton
irradiation. In addition, it was found that HR-deficient cell lines (RAD51 siRNA) were more sensitive
to proton irradiation and similarly had difficulty resolving γH2AX foci, again suggesting a dependence
of the cells to utilize HR for repairing proton-induced lesions. Evidence examining the response of
HeLa cells to 21 MeV protons by immunostaining and high-resolution microscopy demonstrated
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an association of RAD51 with almost every 53BP1 foci 1 h post-irradiation, also indicating that the
proportion of cells undergoing HR following PBT may be higher [46]. Interestingly, when examining
the comparative RBE of 17 non-small-cell lung cancer cell lines in response to 235 MeV protons and
250 kV X-rays, only five of these displayed increased sensitivity to protons and two had confirmed
defects in BRCA1 indicative of a deficiency in HR [47]. The unexpected differences in RBE between
protons and photons was again predicted to be due to differences in the formation of CDD. Given
these opposing findings, more definitive evidence of the DNA repair pathway choice following proton
irradiation is necessary.
Table 2. DNA double strand break (DSB) repair pathway choice following proton beam therapy (PBT)
versus photon irradiation.
Cell line Irradiations Outcome Ref
Wild-type, HR- and
NHEJ-deficient Chinese hamster
ovary cell lines
200 MeV protons and
137Cs γ-rays
NHEJ is the major pathway for both
photons and low-LET protons [43]
Wild-type and NHEJ-deficient
Chinese hamster ovary cell lines
14.4 MeV plateau
protons and 667 keV
137Cs γ-rays
NHEJ is the major pathway for both
photons and low-LET protons [44]
Wild-type, HR-, and
NHEJ-deficient Chinese hamster
ovary cell lines
138 MeV protons and
200-kV X-rays Dependence on HR following protons [36]
A549 lung cancer; glioblastoma
cells
138 MeV protons and
200 kV X-rays Dependence on HR following protons [45]
HeLa 21 MeV protons Higher proportion of cells undergoingHR following protons [46]
Non-small-cell lung cancer cells 235 MeV protons and250 kV X-rays
HR only partly required following
protons [47]
LET—linear energy transfer; HR—homologous recombination; NHEJ—non-homologous end-joining.
3.5. CDD Formation Following PBT
Given the increase in LET toward the distal edge of the SOBP, this is considered to be particularly
effective in increasing the amount of CDD, which is similar in nature to that observed following heavy-ion
irradiation [31]. CDD is considered equally as effective as DSBs in cell killing due to the difficult nature of
its repair leading to its persistence in cells and tissues [27]; therefore, it should be considered as a crucial
factor in the cellular response to PBT. However, to date, most of the evidence relating to CDD formation
specifically following proton irradiation is indirect. Indeed, through Monte Carlo simulations, and by
examining DNA damage clustering with increasing PBT energies (500 keV–50 MeV) and, thus, decreasing
LET, the amount and size of both complex SSBs and complex DSBs were found to decrease [48]. Similarly,
the relative frequencies of complex SSBs and DSBs were also shown to increase proportionally with
increasing LET, which is dependent on proton energy [49,50]. A biophysical model of radiation-induced
cell death and chromosomal aberrations based on the critical role of CDD, and compared to experimental
data in AG01522 and V79 cells following irradiation with 62 MeV protons predicted that these end-points
increased along the SOBP and were highest at the distal fall-off due to low-energy protons [6]. Cell death
at a 2 Gy dose was calculated to increase ~1.5-fold and chromosome aberrations (dicentrics per cell)
increased ~4-fold at the distal fall-off compared to the entrance dose. Additionally, more recently, Monte
Carlo simulations were utilized to examine unrepaired DSBs 24 h after proton irradiation, which were
observed to increase ~1.5-fold (2 Gy) and 1.7-fold (5 Gy) toward the distal fall-off of the SOBP at higher
LET, predictably through increased DSB complexity [51].
In relation to experimental evidence, apart from observations of changes in RBE via clonogenic
survival assays, which are suggestive of CDD formation, direct evidence is lacking, as CDD is
notoriously difficult to measure and specifically define in terms of the nature of DNA damage
complexity in vivo [21,52]. However in SQ23B HNSCC cells CDD, specifically complex DSBs measured
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by utilizing the Escherichia coli enzymes Fpg and Nth for excision of residual oxidative DNA base
damage prior to pulse-field gel electrophoresis, was found to be ~1.2-fold higher for PBT at 76 MeV,
but not 201 MeV, in comparison to γ-irradiation [9]. Interestingly, CDD formation did not depend on
the position of irradiation in the SOBP, which conflicts with other reported data. In particular, it was
demonstrated in AG01522 skin fibroblasts that persistent 53BP1 foci, as a marker of DSBs, was evident
when cells were irradiated at the distal end of the SOBP of a 60 MeV proton beam in comparison to cells
irradiated at the entrance dose or at the Bragg peak itself [35]. These persistent foci were evident at
24 h post-irradiation with Bragg peak protons and were elevated ~2-fold in comparison to the entrance
dose and to 225 kV X-ray irradiation. This is supported by observations of a delay in resolving γH2AX
and 53BP1 foci in TrC1 prostate cancer cells and murine embryonic fibroblasts irradiated at the Bragg
peak (31 MeV) compared to those irradiated at the entrance dose (187 MeV) [34]. Whilst the initial
numbers of γH2AX and 53BP1 foci under the comparative conditions were observed to be the same,
there were significantly (~1.1–1.3-fold) higher levels of foci particularly at 1–4 h post-irradiation in cells
irradiated at the Bragg peak, and these foci were also shown to be on average ~1.3-fold larger in size at
0.5 h and 6 h post-irradiation. However, all foci, indicative of DSB levels, were shown to be resolved
by 24 h irrespective of the irradiation set-up. These two studies are suggestive of the formation of
complex DSBs, particularly at higher LET, which have a longer lifetime to resolve, although direct
evidence for this was not presented. More recently, we described utilization of different versions of the
comet assay to directly demonstrate that CDD is generated in HeLa and HNSCC cells by low-energy
protons (11 MeV mean energy incident on the cells; relatively high-LET) at the distal edge of an SOBP,
in comparison to the cells irradiated at the entrance of a proton beam (58 MeV mean energy; low
LET) that do not [37]. In particular, using an alkaline version of the comet assay, we showed that
low-energy protons caused a reduced rate of repair of cellular SSBs and alkali-labile sites, suggesting
that CDD was largely SSB/abasic site in nature. Under these conditions, we observed that SSB levels
in cells were ~4–7-fold higher 2 h post-irradiation in comparison to cells irradiated with 58 MeV
protons. Interestingly, there was no defect in the repair of DSBs visualized using the neutral comet
assay. Furthermore, an enzyme-modified neutral comet assay employing recombinant DNA repair
enzymes to excise any residual oxidative DNA base damage and abasic sites in association with DSBs
confirmed direct evidence that CDD is formed by low-energy protons generated at the distal end of
the SOBP. We demonstrated that CDD formation in HeLa cells was increased by ~1.3-fold immediately
post-irradiation with low-energy protons versus 58 MeV protons, and that this damage persisted for at
least 4 h post-irradiation. These findings altogether highlight the ability of PBT to induce potentially
more lethal CDD at and around the Bragg peak where the highest LET occurs.
3.6. Cellular Response to CDD Generated by PBT
CDD sites are considered lethal, although this very much depends on the degree of complexity
and the nature of the damage. Indeed, given that, broadly speaking, these are likely to consist of
either complex SSBs or complex DSBs, the cellular response to these may require multiple DNA
repair pathways and proteins, including, as indicated above (Figure 2), a combination of BER and
NHEJ/HR [22,27]. However, despite an appreciation that CDD is a critical factor in the radiobiology of
PBT, the cellular response to CDD induced by PBT, particularly with increasing LET along the SOBP, is
surprisingly understudied. Predictably, there should be a signaling (DDR) mechanism within cells,
similar to γH2AX for DSBs, which is responsible for promoting the repair of CDD sites. We recently
reported for the first time that monoubiquitylation of lysine 120 on histone H2B is promoted in HeLa
and HNSCC cells in response to CDD induced by low-energy (11 MeV mean energy incident on the
cells) protons at the distal edge of an SOBP, catalyzed by the E3 ubiquitin ligases ring finger 20/40
complex (RNF20/40) and male-specific lethal 2 homolog (MSL2) [37]. In fact, levels of histone H2B
ubiquitylation increased by ~1.3–1.6-fold in HeLa cells and ~1.6–2.2-fold in HNSCC cells at 3–6 h
post-irradiation. We demonstrated that this mechanism is important for the efficient repair of CDD
sites, as revealed by delayed repair and significant persistence of CDD induced by low-energy protons
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in RNF20/40 and MSL2 siRNA-depleted cells using the enzyme-modified neutral comet assay, where
CDD levels were ~2.3-fold higher compared to the non-targeting control siRNA treated cells at 4 h
post-irradiation. Furthermore, RNF20/40 and MSL2 were shown to be required for promoting cell
survival under these conditions, as revealed by clonogenic assays. We, therefore, believe that this
is a mechanism for signaling recruitment of DNA repair proteins and/or for chromatin remodeling
necessary for CDD repair (Figure 3). We also described possible evidence that other chromatin
changes, particularly through histone trimethylation, are evident following irradiation of cells with
low-energy protons; however, whether this is directly related to CDD repair is currently unknown.
As a development of these findings, we also recently performed siRNA screening of deubiquitylation
enzymes (DUBs) to further identify the specific enzymes controlling protein ubiquitylation that are
involved in modulating cell survival in response to CDD induced by low energy (11 MeV; relatively
high LET) protons at the distal edge of an SOBP, versus more simple DNA damage generated by both
low-LET (58 MeV) protons and 100 kV X-ray irradiation [41]. This study revealed that ubiquitin-specific
protease 6 (USP6) is required to promote survival in HeLa and HNSCC cells specifically in response to
low-energy protons, and that this effect is mediated through stabilization of the SSB repair protein
PARP-1 required for efficient CDD repair. In fact, levels of CDD were ~1.8-fold higher in USP6
siRNA-depleted cells compared to the non-targeting control siRNA treated cells at 4 h post-irradiation.
This evidence was strengthened and mimicked using the PARP inhibitor olaparib, or through depletion
of PARP-1 using siRNA, which was demonstrated to increase the radiosensitivity of cells to low-energy
protons as a consequence of a significant deficiency in CDD repair. This correlates with our previous
evidence suggesting that CDD generated under these conditions is largely SSB in nature [37], and that
PARP-1 plays a critical role in its repair. However, our study revealed significant synergy between
PARP inhibition and CDD induced by low-energy protons in enhancing cancer cell killing. Predictably,
there is also dependence on other proteins in the BER pathway (such as APE1, Pol β, and XRCC1–Lig
IIIα; Figure 2A) required to promote CDD repair.
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Figure 3. Proposed model for the cellular response to complex DNA damage (CDD) induced by
proton beam therapy (PBT) in chromatin. O i uction of CDD, this triggers monoubiquitylation
of histone H2B on lysine 120 (Ub) by E3 ubiquitin ligases ring finger 20/40 complex (RNF20/40)
and male-specific lethal 2 homolog (MSL2). This stimulates recruitment of the necessary DNA repair
proteins and/or chromatin remodeling factors that promote CDD accessibility. Poly(ADP-ribose)
polymerase-1 (PARP-1) in particular is essential for efficient CDD repair. Our evidence also suggests
the involvement of histone trimethylation (Me) and predictably a deubiquitylation enzyme (DUB) that
is able to regulate access to CDD. Repair then proceeds through the respective DNA repair pathway
dependent on the nature of the damage, although we suggest a particular dependence on the base
excision repair (BER) pathway in the cellular response to high-LET protons, prior to subsequent
chromatin assembly.
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Previous studies of CDD have largely focused on high-LET heavy-ion irradiations. Here, these
have demonstrated that in irradiated cells, CDD increases with increasing LET, but that these are
predominantly unrepairable CDD that generate either chromosome aberrations through the lack of
cell-cycle checkpoint activation or drive cells into senescence [53,54]. Therefore, it is important not
to draw direct parallels between the unrepairable, highly complex CDD generated by heavy ions,
and CDD sites generated by PBT which are likely to be less complex in nature and indeed repairable.
Furthermore, it is thought that CDD may also be prone to generating increases in mutation frequency
due to abortive or slow repair of CDD sites [55]. Nevertheless, due to technical limitations and lack of
experimental studies in this area, we do not have a full appreciation of the cellular response to CDD
specifically generated by PBT at different energies along the radiation track, and whether the nature
of the damage, particularly toward the distal edge, is of sufficient complexity to drive mutagenesis
and/or chromosomal aberrations. Therefore, more extensive research in this area is necessary.
4. Conclusions and Outlook
The utilization of PBT for cancer treatment is increasing worldwide and is appreciated to
be advantageous over conventional radiotherapy as the maximum energy deposition occurs in a
well-defined region (the Bragg peak) that can be specifically targeted to the tumor, which minimizes
unnecessary irradiation of the surrounding normal tissues and OAR. However, there are still
uncertainties with the radiobiology of PBT along the track of the proton beam and particularly
the generation of high-LET protons at the distal edge that can have a greater impact on the molecular
and cellular effects. Therefore, there is an urgent need to further understand the biological effects of
PBT, and particularly to understand the impact on DNA and how this varies with LET. Indeed, whilst
it is widely accepted that CDD is induced at the distal edge of the SOBP, there is little information
on the nature of the damage (e.g., DSB- or SSB-associated) related to proton energy/LET, and how
cells are able to process this through cellular DDR pathways. This is challenging given that CDD is
difficult to measure in vivo; thus, new strategies need to be devised to tackle this problem. There is
also conflicting evidence that simple DSBs induced by PBT are largely repaired by HR, in contrast to
NHEJ which is employed in response to photon irradiation, and whether this is cell-type-dependent.
Furthermore, there are potential differences in the levels of ROS and impact of cell-cycle progression
between protons and photons, although again more experimental data are required to substantiate
these findings. These essential studies have to be carefully designed, particularly as cancer cell lines
frequently have defects in DNA repair and in the cellular DDR; furthermore, irradiation of cells in
specific cell-cycle phases must be taken into account given the dependence of cells to largely utilize HR
in S/G2 phases.
Another consideration is that additional experimental models and techniques need to be utilized
in PBT research, rather than the conventional in vitro experiments using cultured monolayer cell
lines mostly used to assess clonogenic survival post-irradiation. Increasingly, three-dimensional (3D)
models are being employed in translational research, which more accurately reflect the structure
and environment of the original tumor. Therefore, either 3D spheroid models of cancer cell lines, or
multicellular spheroids encapsulating the tumor cells within the correct cellular microenvironment
should be used to examine spheroid growth in response to PBT. These models will also allow a
further examination of PBT radiobiology in terms of the types of DNA damage (e.g., DSBs and CDD)
induced throughout the SOBP, the DNA repair pathways essential for their repair, and the impact of
combinations of targeted drugs or inhibitors (e.g., those targeting the DDR [56]) with PBT in effective
suppression of 3D spheroid growth. The next level would be to employ patient-derived organoids for
examining how these respond to PBT in vitro, and possibly in the future to use these as predictive
models for determining tumor response and ultimately patient outcome to PBT. Finally, more in vivo
experiments employing xenograft models to assess growth of specific tumors following PBT, such as
those conducted using HNSCC [57], should be conducted. These additional models and experiments
bring their challenges, such as the availability and use of clinical facilities for performing animal
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irradiations, and technical challenges including the precise positioning and delivery of PBT to animals.
In addition, a large proportion of PBT facilities worldwide are not usually equipped with on-site
laboratories to effectively perform biological experiments in vitro and in vivo.
There is also an added level of complexity in terms of considering biological factors that may have
a significant impact on the cellular DDR to PBT, particularly on overall efficacy of the treatment. For
example, tumor hypoxia is well known to represent a barrier to the effectiveness of photon radiotherapy,
although there is evidence that particle therapy with higher LET, particularly carbon ions, has a lower
oxygen enhancement ratio and can, therefore, overcome radioresistance of the tumors. However,
whether PBT, particularly at the Bragg peak and the associated distal edge with higher LET, is able
to have the same impact on experimental models is unclear. Also, the tumor microenvironment is
of particular importance given the recent success of immune checkpoint inhibitors (e.g., targeting
PD-1/PD-L1) and their effective combination with radiotherapy for cancer treatment. However, again,
there is little evidence available to understand the added benefit of immunotherapy strategies in
combination with PBT. Nevertheless, there should be a drive from the clinical and scientific community
to collaborate and engage in driving this preclinical and translational research which will ultimately be
utilized for the optimization and personalization of PBT for patient benefit.
In summary, future PBT research should focus on the following:
• Further understanding of the biological effect of PBT at different energy/LET on the cellular DDR;
• Employing additional in vitro models (e.g., 3D spheroids/organoids) in radiobiology experiments;
• Increased utilization of in vivo experiments employing specific tumor models;
• Consideration of other biological factors (e.g., hypoxia, tumor microenvironment).
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